Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.68 |
| ▸ | HTR3B | O95264 | 3/20 | 0.68 |
| ▸ | HTR3A | P46098 | 3/20 | 0.68 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.68 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.68 |
| ▸ | HTR6 | P50406 | 8/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876567 | 0.98 | HTR3E (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL1641730 | 0.98 | HTR3A (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL7732043 | 0.87 | HTR3A (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL14320628 | 0.85 | MAPT (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5701472 | 0.83 | ALDH1A1 (0.57) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3973132 | 0.82 | HTR3A (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2349863 | 0.82 | HTR3A (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL31652018 | 0.82 | HTR3A (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1397389 | 0.82 | DRD2 (0.60) | HTR6DRD2CYP2C19DRD3LMNA | |
| Hydrochloric Acid SCHEMBL6343779 | 0.81 | KDM4E (0.59) | HTR6DRD2CYP2C19DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163279-A3 | LOW-POWER WIRELESSLY-LINKED RFID TRACKING SYSTEM | ROSE MARK D (US) | 2012-05-10 | — | — | WO | claimed |
| US-20070270432-A1 | Novel Method | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | claimed |
| EP-1471912-A1 | METHOD OF PROMOTING NEURONAL GROWTH | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| EP-1107745-B1 | USE OF 5HT-6 ANTAGONISTS FOR THE TREATMENT OF ADHD | SMITHKLINE BEECHAM PLC (GB) | 2004-10-13 | — | — | EP | claimed |
| WO-2003066056-A1 | METHOD OF PROMOTING NEURONAL GROWTH | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | claimed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | claimed |
| US-20020094979-A1 | Use of 5HT-6 antagonists | REAVILL CHARLES ALAN (GB) | 2002-07-18 | — | — | US | claimed |
| US-6380199-B1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | SMITHKLINE BEECHAN P.L.C. (GB) | 2002-04-30 | — | — | US | claimed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | claimed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3027613-B1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | UNIV JAGIELLONSKI (PL) | 2018-03-28 | — | — | EP | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
| US-5358948-A | Psychological, nervous system disorders | GLAXCO GROUP LIMITED (GB) | 1994-10-25 | — | — | US | disclosed |
| WO-1993006084-A1 | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
| EP-0533267-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | HTR3E 3156/4885HTR3B 3257/4885HTR3A 3281/4885 |
| US-20020094979-A1 | Use of 5HT-6 antagonists | HTR6, HTR2A, HTR1A | HTR3E 13/4885HTR3B 6/4885HTR3A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.